Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms von Yanagitani, Noriko, Uchibori, Ken, Koike, Sumie, Tsukahara, Mika, Kitazono, Satoru, Yoshizawa, Takahiro, Horiike, Atsushi, Ohyanagi, Fumiyoshi, Tambo, Yuichi, Nishikawa, Shingo, Fujita, Naoya, Katayama, Ryohei, Nishio, Makoto

Volltext

Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis von Takagi, Satoshi, Sasaki, Yuki, Koike, Sumie, Takemoto, Ai, Seto, Yosuke, Haraguchi, Mizuki, Ukaji, Takao, Kawaguchi, Tokuichi, Sugawara, Minoru, Saito, Masanori, Funauchi, Yuki, Ae, Keisuke, Matsumoto, Seiichi, Fujita, Naoya, Katayama, Ryohei

Volltext

Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2 von Takagi, Satoshi, Sato, Shigeo, Oh-hara, Tomoko, Takami, Miho, Koike, Sumie, Mishima, Yuji, Hatake, Kiyohiko, Fujita, Naoya

Volltext

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer von Katayama, Ryohei, Kobayashi, Yuka, Friboulet, Luc, Lockerman, Elizabeth L, Koike, Sumie, Shaw, Alice T, Engelman, Jeffrey A, Fujita, Naoya

Volltext

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models von Katayama, Ryohei, Gong, Bo, Togashi, Noriko, Miyamoto, Masaya, Kiga, Masaki, Iwasaki, Shiho, Kamai, Yasuki, Tominaga, Yuichi, Takeda, Yasuyuki, Kagoshima, Yoshiko, Shimizu, Yuki, Seto, Yosuke, Oh-hara, Tomoko, Koike, Sumie, Nakao, Naoki, Hanzawa, Hiroyuki, Watanabe, Kengo, Yoda, Satoshi, Yanagitani, Noriko, Hata, Aaron N., Shaw, Alice T., Nishio, Makoto, Fujita, Naoya, Isoyama, Takeshi

Volltext

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib von Katayama, Ryohei, Friboulet, Luc, Koike, Sumie, Lockerman, Elizabeth L, Khan, Tahsin M, Gainor, Justin F, Iafrate, A John, Takeuchi, Kengo, Taiji, Makoto, Okuno, Yasushi, Fujita, Naoya, Engelman, Jeffrey A, Shaw, Alice T

Volltext

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer von Sakashita, Takuya, Yanagitani, Noriko, Koike, Sumie, Low, Siew‐Kee, Takagi, Satoshi, Baba, Satoko, Takeuchi, Kengo, Nishio, Makoto, Fujita, Naoya, Katayama, Ryohei

Volltext

Dofequidar fumarate sensitizes cancer stem‐like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP‐mediated drug export von Katayama, Ryohei, Koike, Sumie, Sato, Shigeo, Sugimoto, Yoshikazu, Tsuruo, Takashi, Fujita, Naoya

Volltext

Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti‐Aggrus/podoplanin antibodies von Nakazawa, Youya, Takagi, Satoshi, Sato, Shigeo, Oh‐hara, Tomoko, Koike, Sumie, Takami, Miho, Arai, Hiroyuki, Fujita, Naoya

Volltext

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer von Katayama, Ryohei, Sakashita, Takuya, Yanagitani, Noriko, Ninomiya, Hironori, Horiike, Atsushi, Friboulet, Luc, Gainor, Justin F., Motoi, Noriko, Dobashi, Akito, Sakata, Seiji, Tambo, Yuichi, Kitazono, Satoru, Sato, Shigeo, Koike, Sumie, John Iafrate, A., Mino-Kenudson, Mari, Ishikawa, Yuichi, Shaw, Alice T., Engelman, Jeffrey A., Takeuchi, Kengo, Nishio, Makoto, Fujita, Naoya

Volltext

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer von Shimizu, Yuki, Okada, Koutaroh, Adachi, Jun, Abe, Yuichi, Narumi, Ryohei, Uchibori, Ken, Yanagitani, Noriko, Koike, Sumie, Takagi, Satoshi, Nishio, Makoto, Fujita, Naoya, Katayama, Ryohei

Volltext

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity von Yoshizawa, Takahiro, Uchibori, Ken, Araki, Mitsugu, Matsumoto, Shigeyuki, Ma, Biao, Kanada, Ryo, Seto, Yosuke, Oh-hara, Tomoko, Koike, Sumie, Ariyasu, Ryo, Kitazono, Satoru, Ninomiya, Hironori, Takeuchi, Kengo, Yanagitani, Noriko, Takagi, Satoshi, Kishi, Kazuma, Fujita, Naoya, Okuno, Yasushi, Nishio, Makoto, Katayama, Ryohei

Volltext

PRMT5, a Novel TRAIL Receptor-Binding Protein, Inhibits TRAIL-Induced Apoptosis via Nuclear Factor-κB Activation von Tanaka, Hiroshi, Hoshikawa, Yutaka, Oh-hara, Tomoko, Koike, Sumie, Naito, Mikihiko, Noda, Tetsuo, Arai, Hiroyuki, Tsuruo, Takashi, Fujita, Naoya

Volltext

Abstract 3590: Resistance mechanisms to ALK inhibitors von Katayama, Ryohei, Yanagitani, Noriko, Koike, Sumie, Sakashita, Takuya, Kitazono, Satoru, Nishio, Makoto, Okuno, Yasushi, Engelman, Jeffrey A., Shaw, Alice T., Fujita, Naoya

Volltext

MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer von Wei, Xinzhao, Uchibori, Ken, Kondo, Nobuyuki, Utsumi, Takahiro, Takemoto, Ai, Koike, Sumie, Takagi, Satoshi, Yanagitani, Noriko, Nishio, Makoto, Katayama, Ryohei

Volltext

Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response von Sakamoto, Kana, Katayama, Ryohei, Asaka, Reimi, Sakata, Seiji, Baba, Satoko, Nakasone, Hideki, Koike, Sumie, Tsuyama, Naoko, Dobashi, Akito, Sasaki, Makoto, Ichinohasama, Ryo, Takakuwa, Emi, Yamazaki, Rie, Takizawa, Jun, Maeda, Takahiro, Narita, Miwako, Izutsu, Koji, Kanda, Yoshinobu, Ohshima, Koichi, Takeuchi, Kengo

Volltext

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance von Okada, Koutaroh, Araki, Mitsugu, Sakashita, Takuya, Ma, Biao, Kanada, Ryo, Yanagitani, Noriko, Horiike, Atsushi, Koike, Sumie, Oh-hara, Tomoko, Watanabe, Kana, Tamai, Keiichi, Maemondo, Makoto, Nishio, Makoto, Ishikawa, Takeshi, Okuno, Yasushi, Fujita, Naoya, Katayama, Ryohei

Volltext

Abstract 3717: Therapeutic strategies to overcome the crizotinib resistance in ROS1-rearranged lung cancers von Katayama, Ryohei, Kobayashi, Yuka, Koike, Sumie, Fujita, Naoya

Volltext

Abstract B42: Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2 von Takagi, Satoshi, Sato, Shigeo, Oh-hara, Tomoko, Takami, Miho, Koike, Sumie, Fujita, Naoya

Volltext

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistanceResearch in context von Koutaroh Okada, Mitsugu Araki, Takuya Sakashita, Biao Ma, Ryo Kanada, Noriko Yanagitani, Atsushi Horiike, Sumie Koike, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Makoto Maemondo, Makoto Nishio, Takeshi Ishikawa, Yasushi Okuno, Naoya Fujita, Ryohei Katayama

Volltext